Rein Therapeutics releases scientific presentation on IPF candidate LTI-03

Reuters2026/09/04 21:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rein Therapeutics published a scientific presentation outlining its fibrosis pipeline, centered on inhaled IPF candidate LTI-03.
Deck highlights Phase 1b results: 5 mg, 10 mg doses tolerated over 14 days, no treatment-related serious adverse events.
Exploratory biomarker readouts showed nominal significance in 5 markers at 10 mg, 2 at 5 mg, aligned with preclinical findings.
Program update includes an enrolling Phase 2 RENEW trial for LTI-03 in IPF, listed as NCT06968845.
Presentation positions LTI-03 as a caveolin-1 scaffolding domain mimic with dual anti-fibrotic, epithelial-protective activity, delivered by dry powder inhaler.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rein Therapeutics releases scientific presentation on IPF candidate LTI-03

You may also like

Crypto prices